Welcome to our dedicated page for Armata Pharmctcl news (Ticker: ARMP), a resource for investors and traders seeking the latest updates and insights on Armata Pharmctcl stock.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) generates frequent news as a clinical-stage biotechnology company developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. News coverage of Armata often centers on its lead intravenous phage cocktail AP-SA02 for complicated Staphylococcus aureus bacteremia and its multi-phage candidate AP-PA02 targeting Pseudomonas aeruginosa in chronic respiratory disease.
Readers following ARMP news can expect detailed updates on clinical trial milestones, including topline data, late-breaking conference presentations, and regulatory interactions. Recent announcements have described positive Phase 1b/2a results from the diSArm study of AP-SA02, higher and earlier cure rates compared with antibiotics alone, and an End-of-Phase 2 written response from the U.S. Food and Drug Administration supporting advancement of AP-SA02 into a planned Phase 3 superiority study in complicated S. aureus bacteremia.
Armata’s news flow also includes information on manufacturing and infrastructure, such as the formal commissioning of its cGMP phage manufacturing facility in Los Angeles, California, which is intended to support late-stage clinical development and potential commercial production. Financial and corporate updates appear in quarterly results releases, describing grant and award revenue from the U.S. Department of Defense, secured credit agreements with Innoviva Strategic Opportunities LLC, and at-the-market equity offering arrangements.
Additional coverage highlights scientific publications and conference participation, including structural biology work on phage Pa223 in the Journal of Molecular Biology and presentations at IDWeek, the Military Health System Research Symposium, and the Evergreen Phage Meeting. For investors, clinicians, and researchers, this news page offers a centralized view of Armata’s progress in phage therapy, regulatory dialogue, funding developments, and manufacturing readiness. Bookmark this page to review ongoing ARMP press releases, SEC-linked disclosures, and other company communications as they are released.
Armata Pharmaceuticals (NYSE: ARMP) reported Q4 and full-year 2024 results, highlighting significant clinical progress. The company announced positive topline results from its Phase 2 Tailwind study of inhaled AP-PA02 for treating Pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis patients, showing statistically significant bacterial reduction.
Q4 2024 financial highlights include:
- Grant revenue of $1.2M (vs $1.5M in Q4 2023)
- R&D expenses of $8.5M (vs $7.9M in Q4 2023)
- Net income of $2.6M or $0.07 per basic share
- Cash position of $14.8M as of December 31, 2024
The company secured a $10M secured credit agreement with Innoviva Strategic Opportunities in March 2025. Armata also completed enrollment in its Phase 1b/2a diSArm study of AP-SA02 for S. aureus bacteremia, with topline results expected in H1 2025.
Armata Pharmaceuticals (NYSE American: ARMP) has secured a $10 million credit agreement with Innoviva Strategic Opportunities , its largest shareholder. The loan facility comes with a 14.0% annual interest rate and matures on March 12, 2026.
The proceeds will support the development of Armata's lead therapeutic phage candidates: AP-PA02 targeting Pseudomonas aeruginosa infections and AP-SA02 for Staphylococcus aureus infections. The funding will specifically enable the company to complete its Phase 1b/2a trial in acute Staphylococcus aureus bacteremia and prepare for an end-of-Phase 2 FDA meeting.
Additionally, Armata amended three existing credit agreements with Innoviva, extending their maturity dates to March 12, 2026. The company continues to seek additional funding sources, including non-dilutive options, to support late-stage clinical trials.
Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotechnology company specializing in bacteriophage therapeutics, has announced that CEO Dr. Deborah Birx will present at the 7th Annual Bacteriophage Therapy Summit in Boston, MA. The presentation is scheduled for Thursday, March 13, 2025, at 9:00am ET.
The company focuses on developing high-purity pathogen-specific bacteriophage therapeutics to address antibiotic-resistant and difficult-to-treat bacterial infections.
Armata Pharmaceuticals (NYSE: ARMP) announced positive topline results from its Phase 2 Tailwind trial of AP-PA02, an inhaled multi-phage therapeutic for treating chronic pulmonary Pseudomonas aeruginosa infections in non-cystic fibrosis bronchiectasis patients.
The trial demonstrated statistically significant reduction of P. aeruginosa in lung sputum, with effects persisting two weeks after treatment completion. A post-hoc analysis showed significant bacterial reduction at day 17 (P=0.05) and day 24 (P=0.015) compared to placebo. Approximately one-third of subjects treated with phage monotherapy showed at least a 2-log CFU reduction.
The treatment was well-tolerated with mostly mild adverse events, though one possibly related serious adverse event requiring hospitalization was reported. The study suggests AP-PA02 alone could be as effective as combination therapy with antibiotics.
Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotechnology company specializing in bacteriophage therapeutics for antibiotic-resistant bacterial infections, announced that CEO Dr. Deborah Birx will present at the 5th Annual Phage Futures Annual Meeting in Boston, MA. The presentation is scheduled for 1:15pm ET on November 19th, 2024.
Armata Pharmaceuticals announced Q3 2024 results and key developments. The company completed enrollment in two significant clinical trials: the Phase 2 'Tailwind' study of inhaled AP-PA02 for non-cystic fibrosis bronchiectasis, with topline data expected by year-end, and the Phase 1b/2a 'diSArm' study of intravenous AP-SA02 for S. aureus bacteremia, with results expected in Q1 2025. Financial highlights include grant revenue of $3.0M, R&D expenses of $9.5M, and a net loss of $5.5M ($0.15 per share). The company held $17.1M in cash as of September 30, 2024.
Armata Pharmaceuticals (NYSE American: ARMP) has completed enrollment (n=50) for its Phase 1b/2a diSArm study of intravenous AP-SA02, targeting Staphylococcus aureus bacteremia. The study aims to assess the safety, tolerability, and efficacy of AP-SA02, a bacteriophage therapy, as an adjunct to standard antibiotics. Armata expects topline data in Q1 2025, which could support the initiation of a pivotal efficacy trial later that year. Initial findings show no significant adverse events and evidence of in vivo phage amplification in half of the treated subjects. The study is backed by $21.6 million from the Defense Health Agency and the Joint Warfighter Medical Research Program.
FAQ
What is the current stock price of Armata Pharmctcl (ARMP)?
What is the market cap of Armata Pharmctcl (ARMP)?
